1. Computational and Systems Biology
  2. Immunology and Inflammation
Download icon

T cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3 sequences

  1. Asaf Madi
  2. Asaf Poran
  3. Eric Shifrut
  4. Shlomit Reich-Zeliger
  5. Erez Greenstein
  6. Irena Zaretsky
  7. Tomer Arnon
  8. Francois Van Laethem
  9. Alfred Singer
  10. Jinghua Lu
  11. Peter D Sun
  12. Irun R Cohen
  13. Nir Friedman  Is a corresponding author
  1. Weizmann Institute of Science, Israel
  2. Weizmann Institute, Israel
  3. National Cancer Institute, United States
  4. National Institute of Allergy and Infectious Diseases, United States
Research Article
  • Cited 40
  • Views 4,224
  • Annotations
Cite this article as: eLife 2017;6:e22057 doi: 10.7554/eLife.22057

Abstract

Diversity of T cell receptor (TCR) repertoires, generated by somatic DNA rearrangements, is central to immune system function. However, the level of sequence similarity of TCR repertoires within and between species has not been characterized. Using network analysis of high-throughput TCR sequencing data, we found that abundant CDR3-TCRβ sequences were clustered within networks generated by sequence similarity. We discovered a substantial number of public CDR3-TCRβ segments that were identical in mice and humans. These conserved public sequences were central within TCR sequence-similarity networks. Annotated TCR sequences, previously associated with self-specificities such as autoimmunity and cancer, were linked to network clusters. Mechanistically, CDR3 networks were promoted by MHC-mediated selection, and were reduced following immunization, immune checkpoint blockade or aging. Our findings provide a new view of T cell repertoire organization and physiology, and suggest that the immune system distributes its TCR sequences unevenly, attending to specific foci of reactivity.

Article and author information

Author details

  1. Asaf Madi

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3441-3228
  2. Asaf Poran

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  3. Eric Shifrut

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  4. Shlomit Reich-Zeliger

    Department of Immunology, Weizmann Institute, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  5. Erez Greenstein

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  6. Irena Zaretsky

    Department of Immunology, Weizmann Institute, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4161-4677
  7. Tomer Arnon

    Department of Immunology, Weizmann Institute, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  8. Francois Van Laethem

    Experimental Immunology Branch, National Cancer Institute, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Alfred Singer

    Experimental Immunology Branch, National Cancer Institute, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Jinghua Lu

    Structural Immunology Section, National Institute of Allergy and Infectious Diseases, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Peter D Sun

    Structural Immunology Section, National Institute of Allergy and Infectious Diseases, Rockville, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Irun R Cohen

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  13. Nir Friedman

    Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    For correspondence
    nir.friedman@weizmann.ac.il
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9678-3550

Funding

Minerva Foundation

  • Nir Friedman

Federal German Ministry for Education and Research

  • Nir Friedman

I-CORE

  • Nir Friedman

Israel Science Foundation

  • Nir Friedman

M.D. Moross Institute for Cancer Reseach

  • Asaf Madi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#24110116-2) of the Weizmann Institute of Science. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Weizmann Institute of Science. Every effort was made to minimize suffering.

Reviewing Editor

  1. Arup K Chakraborty, Ragon Institute of MGH, MIT and Harvard, United States

Publication history

  1. Received: October 10, 2016
  2. Accepted: July 14, 2017
  3. Accepted Manuscript published: July 21, 2017 (version 1)
  4. Version of Record published: August 11, 2017 (version 2)

Copyright

© 2017, Madi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,224
    Page views
  • 808
    Downloads
  • 40
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Computational and Systems Biology
    2. Human Biology and Medicine
    Michael R Garvin et al.
    Short Report Updated

    Neither the disease mechanism nor treatments for COVID-19 are currently known. Here, we present a novel molecular mechanism for COVID-19 that provides therapeutic intervention points that can be addressed with existing FDA-approved pharmaceuticals. The entry point for the virus is ACE2, which is a component of the counteracting hypotensive axis of RAS. Bradykinin is a potent part of the vasopressor system that induces hypotension and vasodilation and is degraded by ACE and enhanced by the angiotensin1-9 produced by ACE2. Here, we perform a new analysis on gene expression data from cells in bronchoalveolar lavage fluid (BALF) from COVID-19 patients that were used to sequence the virus. Comparison with BALF from controls identifies a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin, angiotensin, key RAS receptors, kinogen and many kallikrein enzymes that activate it, and both bradykinin receptors. This very atypical pattern of the RAS is predicted to elevate bradykinin levels in multiple tissues and systems that will likely cause increases in vascular dilation, vascular permeability and hypotension. These bradykinin-driven outcomes explain many of the symptoms being observed in COVID-19.

    1. Computational and Systems Biology
    2. Neuroscience
    Omer Mazar, Yossi Yovel
    Research Article Updated

    For decades, researchers have speculated how echolocating bats deal with masking by conspecific calls when flying in aggregations. To date, only a few attempts have been made to mathematically quantify the probability of jamming, or its effects. We developed a comprehensive sensorimotor predator-prey simulation, modeling numerous bats foraging in proximity. We used this model to examine the effectiveness of a spectral Jamming Avoidance Response (JAR) as a solution for the masking problem. We found that foraging performance deteriorates when bats forage near conspecifics, however, applying a JAR does not improve insect sensing or capture. Because bats constantly adjust their echolocation to the performed task (even when flying alone), further shifting the signals' frequencies does not mitigate jamming. Our simulations explain how bats can hunt successfully in a group despite competition and despite potential masking. This research demonstrates the advantages of a modeling approach when examining a complex biological system.